Over the past decade, Descemet membrane endothelial keratoplasty (DMEK) has become the standard for the treatment of endothelial diseases, with Fuchs endothelial corneal dystrophy (FECD) being the most common indication.1 Descemet membrane endothelial keratoplasty in eyes with FECD usually results in successful clinical outcomes with low postoperative complication rates.2 Because of the fast and reliable visual rehabilitation after DMEK, the visual threshold for undergoing corneal transplantation has decreased and DMEK is performed in a wide range of FECD stages.3 Currently, surgical indications are based mainly on best-corrected visual acuity, central corneal thickness, and patients’ subjective symptoms.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kocaba V, Oellerich S, Melles GRJ. Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy. JAMA Ophthalmol. 2021;139(4):431–432. doi:10.1001/jamaophthalmol.2020.7041
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.